Discontinued — last reported Q4 '25
West Pharmaceutical Services Contract-Manufactured Products — Total Assets increased by 4.7% to $718.10M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 17.3%, from $612.20M to $718.10M.
Growth in assets relative to revenue may indicate capital-intensive expansion, while stable assets with growing revenue suggest improved asset utilization.
The total value of resources controlled by the contract-manufacturing segment, including property, plant, equipment, inv...
Standard 'Segment Assets' reported in the notes to financial statements for diversified companies.
wst_segment_contract_manufactured_products_assets| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | $443.70M | $480.30M | $527.50M | $612.20M | $627.70M | $667.90M | $685.90M | $718.10M |
| QoQ Change | — | +8.2% | +9.8% | +16.1% | +2.5% | +6.4% | +2.7% | +4.7% |
| YoY Change | — | +8.2% | +9.8% | +16.1% | — | — | — | +17.3% |